Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06897488 · ClinicalTrials.gov registry record · Phase 2

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

A Phase 2 study of Breast Cancer, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
300
Enrollment target
1
Study location

NCT06897488: Recruiting Phase 2 study of Breast Cancer, sponsored by M.D. Anderson Cancer Center.

NCT06897488 is a Phase 2 study of Breast Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 300 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06897488, a Phase 2 study of Breast Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

This clinical research study is to learn about the effects of giving radiotherapy alone after lumpectomy to patients who have early-stage, low-risk breast cancers and who are 60 years of age or older.

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events

Conditions Studied

Interventions

  • RADIATION Adjuvant Radiotherapy

Study Locations (1)

Texas

  • The University of Texas M. D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-07-17
Est. Completion 2030-12-31
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT06897488 shows while recruiting

NCT06897488 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Adjuvant Radiotherapy is the first listed.

NCT06897488 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06897488 about?

NCT06897488 is a clinical study titled "EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial". This clinical research study is to learn about the effects of giving radiotherapy alone after lumpectomy to patients who have early-stage, low-risk breast cancers and who are 60 years of age or older.

What is the current status of trial NCT06897488?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-07-17. Estimated completion is 2030-12-31.

What conditions does trial NCT06897488 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT06897488?

The interventions under investigation include: Adjuvant Radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT06897488?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06897488 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06897488's enrollment target sits among peer trials

300 277th of 1224 higher than 938 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06897488, the US trial registry maintained by the National Library of Medicine. NCT06897488 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.